Resources


December 28, 2020

iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer

BRYAN, Texas, Dec. 28, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Martin B. Brenner, DVM, Ph.D., as its Chief ...

Continue Reading

December 1, 2020

iBio Selected to Produce ATB Therapeutics’ Bioengineered Antibody-Toxin Fusion Proteins

BRYAN, Texas, Dec. 01, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract development and manufacturing organization (“CDMO”), today announced that it has entered into its first ...

Continue Reading

November 24, 2020

iBio Announces Issuance of U.S. Patent Covering Endostatin Peptides for Treating Fibrosis

- Methods for Production in iBio’s FastPharming® System Foundational to Antifibrotic Development Program - BRYAN, Texas, Nov. 24, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract ...

Continue Reading

November 3, 2020

iBio Announces Appointment of Randy J. Maddux as Chief Operating Officer

- Brings >20 Years of Global Biotech Operations and Business Development Experience - BRYAN, Texas, Nov. 03, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing ...

Continue Reading

October 2, 2020

iBio Enters into Agreement with Safi Biosolutions to Develop Growth Factors and Cytokines Using the FastPharming® System

- Project Focused on Proteins used in the Production of Blood Cells -

Continue Reading
1 2 3